A Study of LY3006072 in Healthy Participants

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteers

In brief

The purpose of this study is to evaluate how safe LY3006072 (study drug) is and whether it causes any side effects. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of the study drug. The study drug will be given in the morning or evening with or without a meal. This is the first time that this study drug is being given to humans. This study is for research purposes only and is not intended to treat any medical condition.

Key facts

Study ID

NCT01640249

Run by

Eli Lilly and Company

People needed

18

Starts

2012-07-24

Expected to finish

2012-11-26

Last updated by the study team

2019-08-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Overtly healthy males or females, as determined by medical history and physical examination
• Male participants with a partner of childbearing potential must agree to use barrier protection during sexual intercourse while in the study and for 3 months after the last dose of study drug
• Women must not be pregnant or nursing and must be of non-childbearing potential, due to either surgical sterilization or menopause
• Body mass index between 19.0 and 30.0 kilograms per square meter (kg/m\^2), inclusive

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Evansville, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.